Zoledronic Acid Prevents Bone Loss during Endocrine Therapy
SAN ANTONIO, Dec. 14 -- Premenopausal breast cancer patients receiving adjuvant endocrine therapy did not suffer the substantial bone loss typically seen with such treatment when they were also given zoledronic acid (Zometa), updated results from a randomized clinical trial showed
To read full article: http://www.medpagetoday.com/MeetingC...eeting/tb/7690 |
All times are GMT -7. The time now is 09:37 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021